mCRPC Treatment COE

Risk Stratification in Metastatic Prostate Cancer: The Genomic Approach - Leanne Schimke

Details
Diane Newman hosts Leanne Schimke to explore the complexities of metastatic prostate cancer with a focus on the role of genomics and PARP inhibitors. Dr. Schimke delves into how advancements in genomics are providing new avenues for personalized treatment, although the field lags about a decade behind breast cancer research. She highlights the importance of differentiating between indolent and agg...

Bispecific T-cell Engager (BiTE®) in Development for Treatment of Advanced Prostate Cancer - Oliver Sartor

Details
Oliver Sartor joins Alicia Morgans and discusses the evolving landscape of BiTE ® technology applied to prostate cancer therapy. BiTE is a bispecific T-cell engaging antibody that binds on PSMA and CD3 on the T cells to activate the T cells. Bispecific T-cell engagers are a novel approach to tumor immunotherapy. They discuss the current clinical trials landscape and what is maybe on the horizon fo...

CheckMate 9KD Trial CohortA2 Evaluating Nivolumab + Rucaparib for Chemotherapy-Naïve mCRPC - Daniel Petrylak

Details
In this UroToday discussion, Daniel Petrylak joins Tom Keane highlighting the ESMO 2021 data on CheckMate 9KD cohort A2. This was the final analysis of nivolumab and rucaparib for chemotherapy- naïve metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology; Co-Leader, Cancer Signaling Networks, Yale Cancer Center,...

COSMIC-021 Study: A Breakthrough in Metastatic CRPC Treatment with Cabozantinib and Atezolizumab - Neeraj Agarwal

Details
In a discussion hosted by Alicia Morgans, Neeraj Agarwal delves into the promising results of the COSMIC-021 study. The study focuses on the combination of cabozantinib and atezolizumab for treating patients with metastatic castrate-resistant prostate cancer (mCRPC). Dr. Agarwal highlights the unique inclusion criteria of the study, which required patients to have progressive measurable disease in...

Health-Related Quality of Life (HRQoL) From the Phase 3 VISION Study of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer – Karim Fizazi

Details
Alicia Morgans and Karim Fizazi discuss the VISION trial, evaluating new patient-reported data. This patient-reported health-related quality of life data was presented at ESMO 2021. They discuss the VISION trial design, primary trial endpoints, and the importance of preserving good patient quality of life during advanced prostate cancer treatment. Biographies: Karim Fizazi, MD, Ph.D., is a medical...

Phenotypic Expression of Prostate Specific Membrane Antigen (PSMA) - Evan Yu

Details
Phillip Koo and Evan Yu, discuss the phenotypic expression of PSMA. Phenotypic precision medicine guides physicians in looking at the molecular characteristics of a tumor to identify the optimal personalized treatment for the patient. Drs. Yu and Koo discuss the use of PSMA-PET/CT imaging that may fill the critical gaps in prostate cancer staging and as a biomarker for metabolic concordance or res...

Transforming The Standard of Care for Men With Advanced-Stage PSMA-Positive mCRPC, Published Results from the Phase III VISION Trial - Oliver Sartor

Details
Oliver Sartor, MD, joins Charles Ryan, MD in a conversation about the New England Journal of Medicine publication "Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer" known as the VISION trial. The VISION Trial is an international, open-label, phase 3 trial evaluating 177Lu-PSMA-617 in patients who had metastatic castration-resistant prostate cancer previously treated with a...

Ensuring Patients Have Access to Radium-223 as a Therapeutic Option: The DORA Trial - Michael Morris

Details
Alicia Morgans engages with Michael Morris to delve into the rapidly evolving landscape of radiopharmaceuticals in prostate cancer treatment, highlighting the significance of the VISION data and existing therapies like radium-223. Dr. Morris outlines that the abundance of radiopharmaceutical tools is a "good problem to have," emphasizing that these agents are not one-size-fits-all but have unique...

The State of CRPC Treatment in Spain: Expert Opinions on Enzalutamide and Abiraterone - Elena Castro & Fernando Lopez-Campos

Details
Charles Ryan interviews Elena Castro and Fernando Lopez-Campos. They delve into their real-world data on the management of metastatic castration-resistant prostate cancer (mCRPC) in Spain, specifically focusing on the impact of early PSA progression on overall survival in patients treated with enzalutamide or abiraterone. Drs. Castro and Lopez-Campos discuss the significance of monitoring PSA leve...

Real-World Evidence For Patients with mCRPC Treated with Cabazitaxel - Ronald de Wit

Details
The CARD study was a head-to-head comparison of cabazitaxel chemotherapy versus either abiraterone or enzalutamide in mCRPC patients who had been exposed to one series of the docetaxel chemotherapy cycle and the alternative AR-targeted agents. There was a 30% reduction in the risk of death by cabazitaxel chemotherapy. This data was presented at the 2019 ESMO meeting by Ronald de Wit, MD, Ph.D. In...